NO20050162L - Nye antagonister av CXCR3-bindene CXC-kjemokiner - Google Patents
Nye antagonister av CXCR3-bindene CXC-kjemokinerInfo
- Publication number
- NO20050162L NO20050162L NO20050162A NO20050162A NO20050162L NO 20050162 L NO20050162 L NO 20050162L NO 20050162 A NO20050162 A NO 20050162A NO 20050162 A NO20050162 A NO 20050162A NO 20050162 L NO20050162 L NO 20050162L
- Authority
- NO
- Norway
- Prior art keywords
- cxcr3
- cxc chemokines
- chemokines
- binding
- binding cxc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
Abstract
Nye antagonister av CXCR3-bindende CXCkjemokiner og spesielt humant CXCLI I kan oppnås gjennom dannelsen av mutanter av slike kjemokiner hvori bindingen til glykosaminoglykaner (GAG'er) er svekket som følge av ikke-konservative substitusjoner av aminosyrer involvert i denne interaksjonen. Forbindelser fremstilt i henhold til den foreliggende oppfinnelse kan anvendes for å blokkere aktiviteten til CXCR3-bindende CXCkjemokiner på CXCR3-uttrykkende celler og derved tilveiebringe terapeutiske preparater for anvendelse i behandlingen eller forebyggingen av sykdommer relatert til overdreven aktivert T-cellemigrering, slik som ved transplantatavstøtning og autoimmune sykdommer, og av sykdommer med behov for økt vaskularisering, slik som ischemisk hjertesykdom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02100697 | 2002-06-12 | ||
PCT/EP2003/050211 WO2003106488A2 (en) | 2002-06-12 | 2003-06-03 | Novel antagonists of cxcr3-binding cxc chemokines |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20050162L true NO20050162L (no) | 2005-01-12 |
NO332309B1 NO332309B1 (no) | 2012-08-20 |
Family
ID=29724537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050162A NO332309B1 (no) | 2002-06-12 | 2005-01-12 | Antagonister av CXCRX3-bindene CXC-kjemokiner, samt fremgangsmate for fremstilling derav, DNA molekyler kodende for nevnte antagonister, ekspresjonsvektor, vertcelle, farmasoytisk preparat og anvendelse av nevnte antagonister. |
Country Status (16)
Country | Link |
---|---|
US (1) | US7541435B2 (no) |
EP (1) | EP1515990B1 (no) |
JP (1) | JP4394569B2 (no) |
AR (1) | AR040200A1 (no) |
AT (1) | ATE359297T1 (no) |
AU (1) | AU2003255505B2 (no) |
CA (1) | CA2489298C (no) |
CY (1) | CY1106799T1 (no) |
DE (1) | DE60313168T2 (no) |
DK (1) | DK1515990T3 (no) |
ES (1) | ES2282666T3 (no) |
IL (1) | IL165727A (no) |
NO (1) | NO332309B1 (no) |
PT (1) | PT1515990E (no) |
SI (1) | SI1515990T1 (no) |
WO (1) | WO2003106488A2 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045525A2 (en) * | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
US20090208486A1 (en) * | 2004-03-09 | 2009-08-20 | Makoto Taketo | Pharmaceutical composition comprising cxcr3 inhibitor |
ITFI20040243A1 (it) * | 2004-11-25 | 2005-02-25 | Paola Romagnani | Metodo diagnostico per la previsione di rigetto di organo trapiantato |
WO2006069449A1 (en) * | 2004-12-29 | 2006-07-06 | The University Of British Columbia | Chemokine receptor-independent immunomodulatory and anti-proliferative activity |
WO2006125077A2 (en) * | 2005-05-18 | 2006-11-23 | Intermune, Inc. | Non-natural chemokine receptor ligands and methods of use thereof |
EP2136832B1 (en) | 2007-03-26 | 2015-09-02 | General Regeneratives Limited | Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
WO2008149354A2 (en) * | 2007-06-04 | 2008-12-11 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of inflammatory diseases and methods of using same |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
WO2016176583A1 (en) * | 2015-04-29 | 2016-11-03 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
GB202214951D0 (en) * | 2022-10-11 | 2022-11-23 | Univ London Queen Mary | CXC receptor ligands |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
US5656724A (en) | 1994-10-26 | 1997-08-12 | Repligen Corporation | Chemokine-like proteins and methods of use |
US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
US5977334A (en) | 1997-09-11 | 1999-11-02 | The Cleveland Clinic Foundation | DNA encoding a chemokine, Beta R1, comprising the Beta R1 promoter |
WO2001078708A1 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Treating graft rejection with cxcr3 inhibitors |
AU2002218769A1 (en) | 2000-07-12 | 2002-01-21 | Gryphon Therapeutics, Inc. | Chemokine receptor modulators, production and use |
US20020111290A1 (en) * | 2000-12-01 | 2002-08-15 | Bernhard Homey | Uses of mammalian genes and related reagents |
-
2003
- 2003-06-03 SI SI200330798T patent/SI1515990T1/sl unknown
- 2003-06-03 EP EP03759978A patent/EP1515990B1/en not_active Expired - Lifetime
- 2003-06-03 DE DE60313168T patent/DE60313168T2/de not_active Expired - Lifetime
- 2003-06-03 PT PT03759978T patent/PT1515990E/pt unknown
- 2003-06-03 WO PCT/EP2003/050211 patent/WO2003106488A2/en active IP Right Grant
- 2003-06-03 AT AT03759978T patent/ATE359297T1/de active
- 2003-06-03 DK DK03759978T patent/DK1515990T3/da active
- 2003-06-03 US US10/517,726 patent/US7541435B2/en not_active Expired - Fee Related
- 2003-06-03 ES ES03759978T patent/ES2282666T3/es not_active Expired - Lifetime
- 2003-06-03 JP JP2004513319A patent/JP4394569B2/ja not_active Expired - Fee Related
- 2003-06-03 CA CA2489298A patent/CA2489298C/en not_active Expired - Fee Related
- 2003-06-03 AU AU2003255505A patent/AU2003255505B2/en not_active Ceased
- 2003-06-11 AR ARP030102092A patent/AR040200A1/es active IP Right Grant
-
2004
- 2004-12-12 IL IL165727A patent/IL165727A/en not_active IP Right Cessation
-
2005
- 2005-01-12 NO NO20050162A patent/NO332309B1/no not_active IP Right Cessation
-
2007
- 2007-06-28 CY CY20071100857T patent/CY1106799T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2489298A1 (en) | 2003-12-24 |
US7541435B2 (en) | 2009-06-02 |
IL165727A0 (en) | 2006-01-15 |
AU2003255505A1 (en) | 2003-12-31 |
WO2003106488A3 (en) | 2004-04-15 |
EP1515990A2 (en) | 2005-03-23 |
WO2003106488A2 (en) | 2003-12-24 |
PT1515990E (pt) | 2007-05-31 |
IL165727A (en) | 2010-05-17 |
SI1515990T1 (sl) | 2007-08-31 |
US20060204498A1 (en) | 2006-09-14 |
EP1515990B1 (en) | 2007-04-11 |
AU2003255505B2 (en) | 2009-01-08 |
JP4394569B2 (ja) | 2010-01-06 |
ES2282666T3 (es) | 2007-10-16 |
NO332309B1 (no) | 2012-08-20 |
DE60313168D1 (de) | 2007-05-24 |
DK1515990T3 (da) | 2007-06-11 |
ATE359297T1 (de) | 2007-05-15 |
CY1106799T1 (el) | 2012-10-24 |
JP2006511200A (ja) | 2006-04-06 |
CA2489298C (en) | 2012-09-11 |
AR040200A1 (es) | 2005-03-16 |
DE60313168T2 (de) | 2007-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050162L (no) | Nye antagonister av CXCR3-bindene CXC-kjemokiner | |
NO20052272L (no) | CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom | |
HUP0200353A2 (hu) | Fehérje, vérlemezkék tapadásának gátlására | |
Montes et al. | Analysis of the association of IL1B (C+ 3954T) and IL1RN (intron 2) polymorphisms with dental implant loss in a Brazilian population | |
BR0016154A (pt) | Depsipeptida e seus congêneres papa uso como imunossupressores | |
TR199900318T2 (xx) | IL-8 resept�r antagonistleri. | |
BR0207952A (pt) | Moduladores da atividade de receptores de quimiocina | |
DE602004023725D1 (de) | Muteine von tränen-lipocalin | |
ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
RU92016534A (ru) | Синергетические терапевтические композиции и способы достижения синергетического терапевтического эффекта | |
Hume | Effect of eugenol on constrictor responses in blood vessels of the rabbit ear | |
BRPI0415290A (pt) | uso terapêutico de variantes de quimiocina | |
HUP0003505A2 (hu) | Aminoterminálisa felől csonkolt RANTES, mint kemokinantagonista | |
RS89104A (en) | Novel antagonists of mcp proteins | |
ATE231852T1 (de) | Bicyclische aromatische verbindungen | |
MX9307983A (es) | Derivados de aminoacidos de heterociclos como inhibidores de la proteina quinasa c. | |
MX2022007351A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos. | |
ATE321856T1 (de) | Humane rezeptortyrosinkinase | |
ATE81467T1 (de) | Immunosuppression bei der auf immunotoxin basierten behandlung von menschen. | |
ATE289611T1 (de) | Peptide und pharmazeutische zusammensetzungen, die diese enthalten | |
JP2005529067A5 (no) | ||
HK1068256A1 (en) | Compositions comprising organic extracts of geum japonicum thunb var. and the use thereof | |
NO20033541L (no) | Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer | |
CA2487331A1 (en) | Anti-inflammatory compositions and methods of use | |
IL175019A0 (en) | Cxcl8 antagonists, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
MM1K | Lapsed by not paying the annual fees |